OpenEvidence Adds FDA-Cleared EchoNext AI for Heart Disease
- •Pathway Labs received FDA clearance for EchoNext, an AI tool for detecting six forms of structural heart disease.
- •EchoNext identifies heart conditions via EKG analysis by detecting valve blockages and impaired chamber pumping performance.
- •Pathway Labs is licensing the FDA-cleared technology to the medical search engine OpenEvidence for broad clinical distribution.
Doctors using the medical search engine OpenEvidence will soon have access to EchoNext, an AI model capable of detecting six forms of structural heart disease from electrocardiogram (EKG) images. The tool predicts conditions such as valvular blockages and impaired chamber pumping function, providing clinical support by analyzing standard heart rhythm traces.
Developed by researchers at New York-Presbyterian Hospital and Columbia University, the technology is being commercialized by the spinout company Pathway Labs. This month, Pathway Labs secured a sweeping Food and Drug Administration (FDA) clearance for the EchoNext model. In addition to direct sales targeting hospitals, Pathway Labs will license the software to OpenEvidence, a platform serving hundreds of thousands of clinicians. The integration aims to streamline diagnostic workflows by allowing providers to upload EKG images for algorithmic assessment. This marks a strategic expansion of AI-driven diagnostic tools into widely used medical reference platforms.